Estrogens and antiestrogens as etiological factors and therapeutics for prostate cancer

Annals of the New York Academy of Sciences

Volumn 1089, Issue , 2006, Pages 177-193

  Ho, Shuk Mei ^a   Leung, Yuet Kin ^a,b   Chung, Irving ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Antiestrogens; Apigenin; Apoptosis; Developmental reprogramming; DNA methylation; Estrogen receptor; Genomic damages; Licorice; Nuclear receptor coregulators; Oxidative stress; Phytoestrogen; Prostate cancer risk; Selective estrogen receptor modulator (SERM)

Indexed keywords

2 METHOXYESTRADIOL; ANDROGEN; ANTIESTROGEN; ANTISENSE OLIGONUCLEOTIDE; APIGENIN; APVE2; CYTOSINE; DIETHYLSTILBESTROL; ESTRAMUSTINE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; GENISTEIN; GLYCYRRHIZA EXTRACT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LICOCHALCONE A; PHYTOESTROGEN; RALOXIFENE; RESVERATROL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SMALL INTERFERING RNA; TAMOXIFEN; TOREMIFENE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SP2; UNCLASSIFIED DRUG;

ADULTHOOD; BIOGENESIS; BIOLOGICAL ACTIVITY; CANCER HORMONE THERAPY; CANCER RISK; CARCINOGENESIS; CARDIOTOXICITY; CELL PROLIFERATION; CONFERENCE PAPER; CPG ISLAND; DETOXIFICATION; DEVELOPMENTAL STAGE; DNA METHYLATION; DRUG DESIGN; DRUG MECHANISM; ETHNIC DIFFERENCE; EXPERIMENTAL STUDY; GROUPS BY AGE; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HUMAN; METASTASIS; NONHUMAN; PRENATAL PERIOD; PROSTATE; PROSTATE CANCER; PROTEIN BINDING; RACE DIFFERENCE; SIGNAL TRANSDUCTION; TRANSACTIVATION; UNSPECIFIED SIDE EFFECT; GENETICS; GROWTH, DEVELOPMENT AND AGING; MALE; METABOLISM; PHYSIOLOGY; PROSTATE TUMOR; REVIEW;

GLYCYRRHIZA;

CPG ISLANDS; DNA METHYLATION; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS;

EID: 33847788504     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1386.005     Document Type: Conference Paper

References (138)

1. BOSTWICK, D.G., H.B. BURKE, D. DJAKIEW, et al. 2004. Human prostate cancer risk factors. Cancer 101: 2371-2490.
2. HO, S.M., K. LANE & K. LEE. 1997. Neoplastic transformation of the prostate. In Prostate: Basic and Clinical Aspects. Rajesh K Naz, Ed.: 74-114. CRC Press. New York.
3. HO, S.M. 2004. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J. Cell Biochem. 91: 491-503.
4. PRINS, G.S. 2000. Molecular biology of the androgen receptor. Mayo Clin. Proc. 75(Suppl): S32-S35.
5. RISBRIDGER, G.P., J.J. BIANCO, S.J. ELLEM & S.J. MCPHERSON. 2003. Oestrogens and prostate cancer. Endocr. Relat. Cancer 10: 187-191.
6. TAPLIN, M.E. & S.M. HO. 2001. Clinical review 134: The endocrinology of prostate cancer. J. Clin. Endocrinol. Metab. 86: 3467-3477.
7. ROSS, R., L. BERNSTEIN, H. JUDD, et al. 1986. Serum testosterone levels in healthy young black and white men. J. Natl. Cancer Inst. 76: 45-48.
8. DE JONG, F.H., K. OISHI, R.B. HAYES, et al. 1991. Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study. Cancer Res. 51: 3445-3450.
9. DESLYPERE, J.P. & A. VERMEULEN. 1985. Influence of age on steroid concentrations in skin and striated muscle inwomen and in cardiac muscle and lung tissue in men. J. Clin. Endocrinol. Metab. 61: 648-653.
10. FELDMAN, H.A., C. LONGCOPE, C.A. DERBY, et al. 2002. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J. Clin. Endocrinol. Metab. 87: 589-598.
11. GRAY, A., J.A. BERLIN, J.B. MCKINLAY & C. LONGCOPE. 1991. An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. J. Clin. Epidemiol. 44: 671-684.
12. GRAY, A., H.A. FELDMAN, J.B. MCKINLAY & C. LONGCOPE. 1991. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J. Clin. Endocrinol. Metab. 73: 1016-1025.
13. GRIFFITHS, K. 2000. Estrogens and prostatic disease. International Prostate Health Council Study Group. Prostate 45: 87-100.
14. VERMEULEN, A., R. RUBENS & L. VERDONCK. 1972. Testosterone secretion and metabolism in male senescence. J. Clin. Endocrinol. Metab. 34: 730-735.
15. KRIEG, M., R. NASS & S. TUNN. 1993. Effect of aging on endogenous level of 5 alpha-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. J. Clin. Endocrinol. Metab. 77: 375-381.
16. ADAMS, J.Y., I. LEAV, K.M. LAU, et al. 2002. Expression of estrogen receptor beta in the fetal, neonatal, and prepubertal human prostate. Prostate 52: 69-81.
17. HO, S.M., I. LEAV, F.B. MERK, et al. 1995. Induction of atypical hyperplasia, apoptosis, and type II estrogen-binding sites in the ventral prostates of Noble rats treated with testosterone and pharmacologic doses of estradiol-17 beta. Lab. Invest. 73: 356-365.
18. LEAV, I., S.M. HO, P. OFNER, et al. 1988. Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. J. Natl. Cancer Inst. 80: 1045-1053.
19. LEAV, I., F.B. MERK, P.W. KWAN & S.M. HO. 1989. Androgen-supported estrogenenhanced epithelial proliferation in the prostates of intact Noble rats. Prostate 15: 23-40.
20. KAPLAN, P.J., I. LEAV, J. GREENWOOD, et al. 1996. Involvement of transforming growth factor alpha (TGFalpha) and epidermal growth factor receptor (EGFR) in sex hormone-induced prostatic dysplasia and the growth of an androgenin-dependent transplantable carcinoma of the prostate. Carcinogenesis 17: 2571-2579.
21. LEAV, I., F.B. MERK, K.F. LEE, et al. 1999. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. Am. J. Pathol. 154: 863-870.
22. LEAV, I., C.M. GALLUZZI, J. ZIAR, et al. 1996. Mitogen-activated protein kinase and mitogen-activated kinase phosphatase-1 expression in the Noble rat model of sex hormone-induced prostatic dysplasia and carcinoma. Lab. Invest. 75: 361-370.
23. GHATAK, S., P. OLIVERIA, P. KAPLAN & S.M. HO. 1996. Expression and regulation of metallothionein mRNA levels in the prostates of noble rats: lack of expression in the ventral prostate and regulation by sex hormones in the dorsolateral prostate. Prostate 29: 91-100.
24. HO, S.M., I. LEAV, S. GHATAK, et al. 1998. Lack of association between enhanced TRPM-2/clustering expression and increased apoptotic activity in sex-hormone-induced prostatic dysplasia of the Noble rat. Am. J. Pathol. 153: 131-139.
25. GHATAK, S. & S.M. HO. 1996. Age-related changes in the activities of antioxidant enzymes and lipid peroxidation status in ventral and dorsolateral prostate lobes of Noble rats. Biochem. Biophys. Res. Commun. 222: 362-367.
26. HO, S.M. & D. ROY. 1994. Sex hormone-induced nuclear DNA damage and lipid peroxidation in the dorsolateral prostates of Noble rats. Cancer Lett. 84: 155-162.
27. TAM, N.N., S. GHATAK & S.M. HO. 2003. Sex hormone-induced alterations in the activities of antioxidant enzymes and lipid peroxidation status in the prostate of Noble rats. Prostate 55: 1-8.
28. THOMPSON, C.J., N.N. TAM, J.M. JOYCE, et al. 2002. Gene expression profiling of testosterone and estradiol-17 beta-induced prostatic dysplasia in Noble rats and response to the antiestrogen ICI 182,780. Endocrinology 143: 2093-2105.
29. LI, X., E. NOKKALA, W. YAN, et al. 2001. Altered structure and function of reproductive organs in transgenic male mice overexpressing human aromatase. Endocrinology 142: 2435-2442.
30. CHAN, F.L. & S.M. HO. 1999. Comparative study of glycoconjugates of the rat prostatic lobes by lectin histochemistry. Prostate 38: 1-16.
31. CHAN, F.L., H.L. CHOI & S.M. HO. 2001. Analysis of glycoconjugate patterns of normal and hormone-induced dysplastic Noble rat prostates, and an androgen-independent Noble rat prostate tumor, by lectin histochemistry and protein blotting. Prostate 46: 21-32.
32. CAVALIERI, E., K. FRENKEL, J.G. LIEHR, et al. 2000. Estrogens as endogenous genotoxic agents - DNA adducts and mutations. J. Natl. Cancer Inst. Monogr. 75-93.
33. YAGER, J.D. & J.G. LIEHR. 1996. Molecular mechanisms of estrogen carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 36: 203-232.
34. YAGER, J.D. 2000. Endogenous estrogens as carcinogens through metabolic activation. J. Natl. Cancer Inst. Monogr. 67-73.
35. NOCK, N.L., M.S. CICEK, L. LI, et al. 2006. Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk. Carcinogenesis 27: 1842-1848.
36. ACEVEDO, C., J.L. OPAZO, C. HUIDOBRO, et al. 2003. Positive correlation between single or combined genotypes of CYP1A1 and GSTM1 in relation to prostate cancer in Chilean people. Prostate 57: 111-117.
37. CACERES, D.D., J. ITURRIETA, C. ACEVEDO, et al. 2005. Relationship among metabolizing genes, smoking and alcohol used as modifier factors on prostate cancer risk: exploring some gene-gene and gene-environment interactions. Eur. J. Epidemiol. 20: 79-88.
38. QUINONES, L.A., C.E. IRARRAZABAL, C.R. ROJAS, et al. 2006. Joint effect among p53, CYP1A1, GSTM1 polymorphism combinations and smoking on prostate cancer risk: an exploratory genotype-environment interaction study. Asian J. Androl. 8: 349-355.
39. SILIG, Y., H. PINARBASI, S. GUNES, et al. 2006. Polymorphisms of CYP1A1, GSTM1, GSTT1, and prostate cancer risk in Turkish population. Cancer Invest. 24: 41-45.
40. SOBTI, R.C., K. ONSORY, A.I. AL BADRAN, et al. 2006. CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population DNA. Cell Biol. 25: 287-294.
41. SUZUKI, M., M.R. MAMUN, K. HARA, et al. 2005. The Val158Met polymorphism of the catechol-O-methyltransferase gene is associated with the PSA-progression-free survival in prostate cancer patients treated with estramustine phosphate. Eur. Urol. 48: 752-759.
42. TANAKA, Y., M. SASAKI, H. SHIINA, et al. 2006. Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer. Cancer Epidemiol. Biomarkers Prev. 15: 238-244.
43. TANG, Y.M., B.L. GREEN, G.F. CHEN, et al. 2000. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 10: 761-766.
44. LEUNG, Y.K., K.M. LAU, J. MOBLEY, et al. 2005. Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. Cancer Res. 65: 3726-3734.
45. TAM, N.N., Y. GAO, Y.K. LEUNG & S.M. HO. 2006. Induction of NAD(P)H oxidases and nitric oxide synthetases leading to oxidative and nitrosative stresses in hormonal carcinogenesis of the prostate gland in Noble rats [abstract]. Proceedings of the 95th annual meeting of the American Association of Cancer Research, Orlando, Florida, 2004.
46. LAKHANI, N.J., M.A. SARKAR, J. VENITZ & W.D. FIGG. 2003. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 23: 165-172.
47. ELLEM, S.J. & G.P. RISBRIDGER. 2006. Aromatase and prostate cancer. Minerva Endocrinol. 31: 1-12.
48. DI, S.E., G. BRIATICO, D. GIUDICI, et al. 1994. Endocrine properties of the testosterone 5 alpha-reductase inhibitor turosteride (FCE 26073). J. Steroid Biochem. Mol. Biol. 48: 241-248.
49. HIRAMATSU, M., I. MAEHARA, M. OZAKI, et al. 1997. Aromatase in hyperplasia and carcinoma of the human prostate. Prostate 31: 118-124.
50. MATZKIN, H. & M.S. SOLOWAY. 1992. Response to second-line hormonal manipulation monitored by serum PSA in stage D2 prostate carcinoma. Urology 40: 78-80.
51. RADLMAIER, A., H.U. EICKENBERG, M.S. FLETCHER, et al. 1996. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group. Prostate 29: 199-208.
52. SUZUKI, K., H. OKAZAKI, Y. ONO, et al. 1998. Effect of dual inhibition of 5-alpha-reductase and aromatase on spontaneously developed canine prostatic hypertrophy. Prostate 37: 70-76.
53. KRUIT, W.H., G. STOTER & J.G. KLIJN. 2004. Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy. Anticancer Drugs 15: 843-847.
54. SUZUKI, K., H. NAKAZATO, H. MATSUI, et al. 2003. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer 98: 1411-1416.
55. SUZUKI, K., H. NAKAZATO, H. MATSUI, et al. 2003. Association of the genetic polymorphism of the CYP19 intron 4[TTTA]n repeat with familial prostate cancer risk in a Japanese population. Anticancer Res. 23: 4941-4946.
56. MCPHERSON, S.J., H. WANG, M.E. JONES, et al. 2001. Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology 142: 2458-2467.
57. RAJFER, J. & D.S. COFFEY. 1978. Sex steroid imprinting of the immature prostate. Long-term effects. Invest. Urol. 16: 186-190.
58. ARAI, Y., Y. SUZUKI & Y. NISHIZUKA. 1977. Hyperplastic and metaplastic lesions in the reproductive tract of male rats induced by neonatal treatment with diethylstilbestrol. Virchows. Arch. A. Pathol. Anat. Histol. 376: 21-28.
59. ARAI, Y., T. MORI, Y. SUZUKI & H.A. BERN. 1983. Long-term effects of perinatal exposure to sex steroids and diethylstilbestrol on the reproductive system of male mammals. Int. Rev. Cytol. 84: 235-268.
60. PRINS, G.S. 1992. Neonatal estrogen exposure induces lobe-specific alterations in adult rat prostate androgen receptor expression. Endocrinology 130: 3703-3714.
61. VORHERR, H., R.H. MESSER, U.F. VORHERR, et al. 1979. Teratogenesis and carcinogenesis in rat offspring after transplacental and transmammary exposure to diethylstilbestrol. Biochem. Pharmacol. 28: 1865-1877.
62. MCLACHLAN, J.A., R.R. NEWBOLD & B. BULLOCK. 1975. Reproductive tract lesions in male mice exposed prenatally to diethylstilbestrol. Science 190: 991-992.
63. MCLACHLAN, J.A. 1977. Prenatal exposure to diethylstilbestrol in mice: toxicological studies. J. Toxicol. Environ. Health 2: 527-537.
64. PYLKKANEN, L., R. SANTTI, R. NEWBOLD & J.A. MCLACHLAN. 1991. Regional differences in the prostate of the neonatally estrogenized mouse. Prostate 18: 117-129.
65. PRINS, G.S., R.J. SKLAREW & L.P. PERTSCHUK. 1998. Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy. J. Urol. 159: 641-649.
66. PRINS, G.S., L. BIRCH, J.F. COUSE, et al. 2001. Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: studies with alphaERKO and betaERKO mice. Cancer Res. 61: 6089-6097.
67. VOM SAAL, F.S., B.G. TIMMS, M.M. MONTANO, et al. 1997. Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc. Natl. Acad. Sci. USA 94: 2056-2061.
68. HO, S.M., W.Y. TANG, D.F. BELMONTE & G.S. PRINS. 2006. Developmental exposure to estradiol and bisphenol a increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. Cancer Res. 66: 5624-5632.
69. HENDERSON, B.E. & H.S. FEIGELSON. 2000. Hormonal carcinogenesis. Carcinogenesis 21: 427-433.
70. POTISCHMAN, N., R. TROISI, R. THADHANI, et al. 2005. Pregnancy hormone concentrations across ethnic groups: implications for later cancer risk. Cancer Epidemiol. Biomarkers Prev. 14: 1514-1520.
71. EKBOM, A., C.C. HSIEH, L. LIPWORTH, et al. 1996. Perinatal characteristics in relation to incidence of and mortality from prostate cancer. BMJ 313: 337-341.
72. EKBOM, A., J. WUU, H.O. ADAMI, et al. 2000. Duration of gestation and prostate cancer risk in offspring. Cancer Epidemiol. Biomarkers Prev. 9: 221-223.
73. IKEZUKI, Y., O. TSUTSUMI, Y. TAKAI, et al. 2002. Determination of bisphenol A concentrations in human biological fluids reveals significant early prenatal exposure. Hum. Reprod. 17: 2839-2841.
74. KURODA, N., Y. KINOSHITA, Y. SUN, et al. 2003. Measurement of bisphenol A levels in human blood serum and ascitic fluid by HPLC using a fluorescent labeling reagent. J. Pharm. Biomed. Anal. 30: 1743-1749.
75. SCHONFELDER, G., W. WITTFOHT, H. HOPP, et al. 2002. Parent bisphenol A accumulation in the human maternal-fetal- placental unit. Environ. Health Perspect. 110: A703-A707.
76. TSURUSAKI, T., D. AOKI, H. KANETAKE, et al. 2003. Zone-dependent expression of estrogen receptors alpha and beta in human benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. 88: 1333-1340.
77. YAMADA, H., I. FURUTA, E.H. KATO, et al. 2002. Maternal serum and amniotic fluid bisphenol A concentrations in the early second trimester. Reprod. Toxicol. 16: 735-739.
78. NILSSON, S. & J.A. GUSTAFSSON. 2000. Estrogen receptor transcription and transactivation: basic aspects of estrogen action. Breast Cancer Res. 2: 360-366.
79. PETTERSSON, K. & J.A. GUSTAFSSON. 2001. Role of estrogen receptor beta in estrogen action. Annu. Rev. Physiol. 63: 165-192.
80. LEUNG, Y.K., P. MAK, S. HASSAN & S.M. HO. 2006. Estrogen receptor (ER) β isoforms: a key to understanding ER-β signaling. Proc. Natl. Acad. Sci. USA 103: 13162-13167.
81. OSBORNE, C.K., R. SCHIFF, S.A. FUQUA & J. SHOU. 2001. Estrogen receptor: current understanding of its activation and modulation. Clin. Cancer Res. 7: 4338s-4342s.
82. TREMBLAY, G.B. & V. GIGUERE. 2002. Coregulators of estrogen receptor action. Crit. Rev. Eukaryot. Gene Expr. 12: 1-22.
83. LEAV, I., K.M. LAU, J.Y. ADAMS, et al. 2001. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am. J. Pathol. 159: 79-92.
84. FIXEMER, T., K. REMBERGER & H. BONKHOFF. 2003. Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 54: 79-87.
85. HORVATH, L.G., S.M. HENSHALL, C.S. LEE, et al. 2001. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res. 61: 5331-5335.
86. LATIL, A., I. BIECHE, D. VIDAUD, et al. 2001. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res. 61: 1919-1926.
87. ROYUELA, M., M.P. DE MIGUEL, F.R. BETHENCOURT, et al. 2001. Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. J. Endocrinol. 168: 447-454.
88. TORLAKOVIC, E., W. LILLEBY, G. TORLAKOVIC, et al. 2002. Prostate carcinoma expression of estrogen receptor-beta as detected by PPG5/10 antibody has positive association with primary Gleason grade and Gleason score. Hum. Pathol. 33: 646-651.
89. WEIHUA, Z., M. WARNER & J.A. GUSTAFSSON. 2002. Estrogen receptor beta in the prostate. Mol. Cell Endocrinol. 193: 1-5.
90. JIANG, J., H.L. CHANG, Y. SUGIMOTO & Y.C. LIN. 2005. Effects of age on growth and ERbeta mRNA expression of canine prostatic cells. Anticancer Res. 25: 4081-4090.
91. POELZL, G., Y. KASAI, N. MOCHIZUKI, et al. 2000. Specific association of estrogen receptor beta with the cell cycle spindle assembly checkpoint protein, MAD2. Proc. Natl. Acad. Sci. USA 97: 2836-2839.
92. WEIHUA, Z., S. MAKELA, L.C. ANDERSSON, et al. 2001. A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc. Natl. Acad. Sci. USA 98: 6330-6335.
93. SIGNORETTI, S. & M. LODA. 2001. Estrogen receptor beta in prostate cancer: brake pedal or accelerator? Am. J. Pathol. 159: 13-16.
94. KREGE, J.H., J.B. HODGIN, J.F. COUSE, et al. 1998. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc. Natl. Acad. Sci. USA 95: 15677-15682.
95. CHANG, W.Y. & G.S. PRINS. 1999. Estrogen receptor-beta: implications for the prostate gland. Prostate 40: 115-124.
96. MONTANO, M.M. & B.S. KATZENELLENBOGEN. 1997. The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens. Proc. Natl. Acad. Sci. USA 94: 2581-2586.
97. MONTANO, M.M., B.M. WITTMANN & N.R. BIANCO. 2000. Identification and characterization of a novel factor that regulates quinone reductase gene transcriptional activity. J. Biol. Chem. 275: 34306-34313.
98. MONTANO, M.M., H. DENG, M. LIU, et al. 2004. Transcriptional regulation by the estrogen receptor of antioxidative stress enzymes and its functional implications. Oncogene 23: 2442-2453.
99. DIMITROVA, K.R., K.W. DEGROOT, J.P. SUYDERHOUD, et al. 2002. 17-beta estradiol preserves endothelial cell viability in an in vitro model of homocysteine-induced oxidative stress. J. Cardiovasc. Pharmacol. 39: 347-353.
100. GELINAS, S., G. BUREAU, B. VALASTRO, et al. 2004. Alpha and beta estradiol protect neuronal but not native PC12 cells from paraquat-induced oxidative stress. Neurotox. Res. 6: 141-148.
101. MIZE, A.L., R.A. SHAPIRO & D.M. DORSA. 2003. Estrogen receptor-mediated neuroprotection from oxidative stress requires activation of the mitogen-activated protein kinase pathway. Endocrinology 144: 306-312.
102. TREUTER, E., M. WARNER & J.A. GUSTAFSSON. 2000. Mechanism of oestrogen signalling with particular reference to the role of ER beta in the central nervous system. Novartis Found. Symp. 230: 7-14.
103. BIANCO, N.R., L.J. CHAPLIN & M.M. MONTANO. 2005. Differential induction of quinone reductase by phytoestrogens and protection against oestrogen-induced DNA damage. Biochem. J. 385: 279-287.
104. SHAPIRO, E., H. HUANG, R.J. MASCH, et al. 2005. Immunolocalization of estrogen receptor alpha and beta in human fetal prostate. J. Urol. 174: 2051-2053.
105. PASQUALI, D., S. STAIBANO, D. PREZIOSO, et al. 2001. Estrogen receptor beta expression in human prostate tissue. Mol. Cell. Endocrinol. 178: 47-50.
106. PASQUALI, D., V. ROSSI, D. ESPOSITO, et al. 2001. Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues. J. Clin. Endocrinol. Metab. 86: 2051-2055.
107. LAI, J.S., L.G. BROWN, L.D. TRUE, et al. 2004. Metastases of prostate cancer express estrogen receptor-beta. Urology 64: 814-820.
108. ZHU, X., I. LEAV, Y.K. LEUNG, et al. 2004. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am. J. Pathol. 164: 2003-2012.
109. DOMANN, F.E. & B.W. FUTSCHER. 2004. Flipping the epigenetic switch. Am. J. Pathol. 164: 1883-1886.
110. HAQQ, C., R. LI, D. KHODABAKHSH, et al. 2005. Ethnic and racial differences in prostate stromal estrogen receptor alpha. Prostate 65: 101-109.
111. TANAKA, Y., M. SASAKI, M. KANEUCHI, et al. 2003. Polymorphisms of estrogen receptor alpha in prostate cancer. Mol. Carcinogen. 37: 202-208.
112. HUGGINS, C. & C.V. HODGES. 1972. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate CA. Cancer J. Clin. 22: 232-240.
113. COX, R.L. & E.D. CRAWFORD. 1995. Estrogens in the treatment of prostate cancer. J. Urol. 154: 1991-1998.
114. DENIS, L.J. & K. GRIFFITHS. 2000. Endocrine treatment in prostate cancer. Semin. Surg. Oncol. 18: 52-74.
115. BERGAN, R.C., E. REED, C.E. MYERS, et al. 1999. A phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 5: 2366-2373.
116. HAMILTON, M., W. DAHUT, O. BRAWLEY, et al. 2003. A phase I/II study of high-dose tamoxifen in combination with vinblastine in patients with androgenindependent prostate cancer. Acta Oncol. 42: 195-201.
117. LISSONI, P., P. VIGANO, M. VAGHI, et al. 2005. A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretion. Anticancer Res. 25: 3597-3599.
118. SHAZER, R.L., A. JAIN, A.V. GALKIN, et al. 2006. Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. BJU Int. 97: 691-697.
119. STEIN, S., B. ZOLTICK, T. PEACOCK, et al. 2001. Phase II trial of toremifene in androgen-independent prostate cancer: a Penn cancer clinical trials group trial. Am. J. Clin. Oncol. 24: 283-285.
120. EL-RAYES, B.F. & M.H. HUSSAIN. 2002. Hormonal therapy for prostate cancer: past, present and future. Expert. Rev. Anticancer Ther. 2: 37-47.
121. SCHULZ, P., H.W. BAUER, W.P. BRADE, et al. 1988. Evaluation of the cytotoxic activity of diethylstilbestrol and its mono- and diphosphate towards prostatic carcinoma cells. Cancer Res. 48: 2867-2870.
122. KUMAR, A.P., G.E. GARCIA & T.J. SLAGA. 2001. 2-methoxyestradiol blocks cell-cycle progression at G(2)/M phase and inhibits growth of human prostate cancer cells. Mol. Carcinogen. 31: 111-124.
123. QADAN, L.R., C.M. PEREZ-STABLE, C. ANDERSON, et al. 2001. 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cancer. Biochem. Biophys. Res. Commun. 285: 1259-1266.
124. KIM, I.Y., B.C. KIM, D.H. SEONG, et al. 2002. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res. 62: 5365-5369.
125. SHIMADA, K., M. NAKAMURA, E. ISHIDA, et al. 2003. Requirement of c-jun for testosterone-induced sensitization to N-(4-hydroxyphenyl)retinamide-induced apoptosis. Mol. Carcinogen. 36: 115-122.
126. DAHLLOF, B., A. BILLSTROM, F. CABRAL & B. HARTLEY-ASP. 1993. Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res. 53: 4573-4581.
127. KUWAJERWALA, N., E. CIFUENTES, S. GAUTAM, et al. 2002. Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis. Cancer Res. 62: 2488-2492.
128. MATSUKAWA, Y., N. MARUI, T. SAKAI, et al. 1993. Genistein arrests cell cycle progression at G2-M. Cancer Res. 53: 1328-1331.
129. MISRA, R.R., S.D. HURSTING, S.N. PERKINS, et al. 2002. Genotoxicity and carcinogenicity studies of soy isoflavones. Int. J. Toxicol. 21: 277-285.
130. RAFI, M.M., R.T. ROSEN, A. VASSIL, et al. 2000. Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer Res. 20: 2653-2658.
131. LAVALLEE, T.M., X.H. ZHAN, M.S. JOHNSON, et al. 2003. 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res. 63: 468-475.
132. MOR, G., F. KOHEN, J. GARCIA-VELASCO, et al. 2000. Regulation of fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen. J. Steroid Biochem. Mol. Biol. 73: 185-194.
133. LI, Y. & F.H. SARKAR. 2002. Gene expression profiles of genistein-treated PC3 prostate cancer cells. J. Nutr. 132: 3623-3631.
134. LIU, Y., E. KYLE, R. LIEBERMAN, et al. 2000. Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-beta-1-integrin complex formation. Clin. Exp. Metastasis 18: 203-212.
135. NEUBAUER, B.L., K.L. BEST, D.F. COUNTS, et al. 1995. Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model. Prostate 27: 220-229.
136. LAU, K.M., M. LASPINA, J. LONG & S.M. HO. 2000. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res. 60: 3175-3182.
137. MAK, P., Y.K. LEUNG, W.Y. TANG, et al. 2006. Apigenin suppresses cancer cell growth via ERβ. Neoplasia. In press.
138. MOBLEY, J.A., J.O. L'ESPERANCE, M. WU, et al. 2004. The novel estrogen 17alpha-20Z-21-[(4-amino)phenyl]-19-norpregna- 1,3,5(10),20-tetraene-3,17beta-diol induces apoptosis in prostate cancer cell lines at nanomolar concentrations in vitro. Mol. Cancer Ther. 3: 587-595.